Partner With Us NRI

Lupin Ltd share Price Today

Company details

6M Return 34.74%
1Y Return 107.81%
Mkt Cap.(Cr) 73,562.54
Volume 1,083,346
Div Yield 0.49%
OI Chg %
Volume 1,083,346

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Beat on revenues but margins still below par…
About The Stock

    Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.

    • It is the third largest generic player (by prescriptions) in the US (market
    leader: 44 products; Top three: 113 products) besides being the sixth
    largest company in the Indian pharmaceutical market
    • The company continues to face headwinds, especially on the US generics
    front due to persistent price erosion in OSD and plant compliance issues


    Revenue beat led by the US and API business.
    • Revenues grew 14.1% YoY to ₹ 4430 crore
    • EBITDA margins improved 780 bps YoY to 13.6%
    • Adjusted PAT came in at ₹ 253 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Lupin announced Q4FY24 results:

Financial Highlights:

  • Gross Profit was Rs 33,213 million compared to Rs 33,538 million in Q3FY24, with gross margin of 67.8%.
  • Personnel cost was 18.4% of sales at Rs 9,002 million compared to Rs 8,892 million in Q3FY24.
  • Manufacturing and other expenses were 30.4% of sales at Rs 14,901 million compared to Rs 15,602 million in Q3FY24.
  • PBT was lower in Q4FY24 on account of impairment charge of Rs 2,013 million.
  • Investment in R&D for the quarter was Rs 4,255 million (8.7% of sales). 
  • Operating working capital was Rs 56,913 million as on March 31, 2024.
  • Capital Expenditure for the quarter was Rs 1,059 million.
  • Net Debt as on March 31, 2024 stands at Rs 4,766 million.
  • Net Debt-Equity as on March 31, 2024 stands at 0.03. 

Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, “We continue to move forward with sustainable and profitable growth and delivered another strong set of numbers in Q4. Our U.S. sales remain healthy driven by inhalation products, and our India formulation business is delivering ahead of market. While FY24 has been a year of resurgence for the company, we look forward to an even stronger FY25 driven by growth across our key geographies and consistent improvement in our margins”.

Result PDF

View Other Company Results

Lupin Ltd shares SWOT Analysis

Strengths (13)

  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (3)

  • MACD Crossover Below Signal Line
  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (2)

  • Promoter decreasing their shareholding
  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,633.7
R2 1,653.1
R3 1,664.2


S1 1,603.2
S2 1,592.1
S3 1,572.7
Delivery and volume
SOCIETE GENERALE Block Purchase 2024-01-25 1449.2 747956 BSE
BNP PARIBAS ARBITRAGE Block Sell 2024-01-25 1449.2 747956 BSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 747 228477 NSE
Name Category Shares
Manju D Gupta PROMOTER 0.85%
Lupin Investments Pvt Ltd PROMOTER 45.47%


Investment recommendation
Beat on revenues but margins still below par…
Call Date
11 May 2023
Entry Price 760.00
Target Price 740.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Lupin Ltd Stocks COMPARISON

Financials( in Cr) Lupin Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,614.35 1,486.70 1,486.45 4,122.40 1,076.00
% Change -1.12 -0.56 -0.18 0.23 -0.93
Mcap Cr 73,562.54 356,709.13 120,011.07 109,436.94 108,270.78
Revenue TTM Cr 16,641.66 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 447.69 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 38.84 35.84 28.23 78.90 28.33
1 Year Return 107.81 59.59 59.76 21.76 112.04
ROCE 5.70 16.79 14.76 19.30 16.25
ROE 3.64 16.46 10.66 14.89 14.05

Equity Capital: 12,464.50 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 36,628.54 -24,386.86
LAST 3M 102,786.44 -29,845.85
LAST 6M 169,824.52 52,410.32
LAST 12M 264,693.58 128,545.97
Lupin Limited - Updates

May 22, 2024 l NSE Announcement

Lupin allots 1.22 lakh equity shares under ESOP

May 21, 2024 l BSE Announcement

Lupin Limited - ESOP/ESOS/ESPS

May 21, 2024 l NSE Announcement

Date Action Type Ratio
Jul 14, 2023 Dividend 200
Jul 14, 2022 Dividend 200

Lupin Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Lupin Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 44,266.89 crores, it is incorporated in the year 1968. It has a reported consolidated sales of Rs. 4,237.39 crores in June’2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 500257 and also listed in the National Stock Exchange (NSE) with the code LUPIN.

    Lupin Ltd is an Indian international pharmaceuticals company and is one of the largest generic pharmaceuticals companies globally based on revenue. The company primarily focuses on six areas, namely, paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti- tuberculosis. Lupin has a global presence with operations spreading across 11 nations and 6 continents. Lupin has a team of over 1400 scientists working at Research 7 development headquarters located near Pune. Lupin ltd meets its corporate social responsibility through The Lupin Human Welfare & Research Foundation set up in 1988. The foundation mainly focuses on rural development projects that have reached over 3400 villages across eight states in the country to date. The promoters of the company own 46.84% of the stake in the company, Foreign Institutional Investors (FII) own 18.6%, Domestic Institutional Investors (DII) own 22.09% of the stake, and others (such as retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 3,314.12 crores, which has increased by approximately 22.97 % from Rs. 2,695.08 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 645.87 crores, which has seen an increase by nearly 77.64 % from a net profit of Rs. 363.58 crores in June 2020. In June 2021, the reported operating profit was at Rs. 2,617.15 crores, which is also increased by 26.76% as compared to an operating profit of Rs. 2,064.73 crores for the quarter ending in June 2020. From Rs. 8.03 in June 2020, the EPS of Lupin Ltd has almost doubled and reached Rs. 14.13 per share in June 2021. LUPIN’s stock closed at Rs. 974.10 on 17th August’2021 (NSE) and has returned -8.29% in the last six months and -2.83% in the previous year.

Registered Address

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Tel : 91-22-6640 2323
Email : investorservices:lupinpharma.com
Website : http://www.lupinworld.com; www.lupin.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500257
Book Closure Date (Month) :
BSE Group : A
ISIN : INE326A01037

FAQ’s on Lupin Ltd Shares

You can buy Lupin Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lupin Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2024 03:58 PM the closing price of Lupin Ltd was Rs.1,614.35.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 24, 2024 03:58 PM, the market cap of Lupin Ltd stood at Rs. 73,562.54.

The latest PE ratio of Lupin Ltd as of May 24, 2024 03:58 PM is 38.84

The latest PB ratio of Lupin Ltd as of May 24, 2024 03:58 PM is 0.19

The 52-week high of Lupin Ltd share price is Rs. 1,728.00 while the 52-week low is Rs. 773.20

According to analyst recommendations, Lupin Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app